• Login
    View Item 
    •   UNTHSC Scholar
    • Research Appreciation Day
    • 2019
    • Abstracts
    • General Medicine
    • View Item
    •   UNTHSC Scholar
    • Research Appreciation Day
    • 2019
    • Abstracts
    • General Medicine
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Radiofrequency ablation (RFA) for the treatment of refractory gastric antral vascular ectasia: a systematic review and meta-analysis

    Thumbnail
    Date
    2019-03-05
    Author
    Salim, Hamza
    Komandur, Thrupthi
    Shah, Usman
    Turab, Mohammed
    Patil, Pritvhi
    Thosani, Nirav
    Metadata
    Show full item record
    Abstract
    Abstract Purpose: Gastric antral vascular ectasia (GAVE) is an uncommon cause of upper GI bleeding characterized by mucosal and submucosal vascular ectasia that commonly manifests as occult bleeding and chronic anemia. Argon Plasma Coagulation (APC) is frequently used as initial treatment for symptomatic GAVE. APC often requires multiple endoscopies and patients may not have full resolution of symptoms. Radiofrequency ablation (RFA) has emerged as a successful alternative. This study aims to conduct a systematic review and meta-analysis to evaluate the safety and efficacy of RFA in the treatment of GAVE. Methods: A comprehensive search of Pubmed, EMBASE, and Web of Science databases was performed, which focused on reviewing titles/abstracts, choosing relevant studies, and conducting necessary data extrapolation. This search was done on literature from 2008 up until June 2018 and studies with less than 5 patients were excluded. The measured parameters included improved hemoglobin levels, transfusion dependence, RFA treatment modality, adverse events, and number of RFA treatments. Results: We identified a total of 8 studies (N=128 patients) that used RFA for refractory GAVE. The HALO-90 or HALO-ULTRA ablation catheter (Covidien, GI Solutions, Sunnyvale, CA, USA), with a power capacity of 10-15 J/cm2, were the treatment modalities used. The overall clinical success rate for RFA in treatment for refractory GAVE was 68% (59%-76%, I2 value for heterogeneity 0). Average pre-treatment Hb value increased significantly from 8.03 (6.88-9.18, I2 94) to 10.38 (9.49-11.27, I2 77) after the RFA treatment. This difference was statistically significant: Standardize difference in mean 1.92 (0.50-3.35, p Conclusions: RFA can be an effective alternative in treatment for GAVE refractory to APC. While long-term data is limited, the evidence shows improved Hemoglobin levels and decreased transfusion dependence in treated patients. Further controlled trials are needed to compare the long-term safety, efficacy, and cost-effectiveness between RFA and APC in the treatment of GAVE and CRP.
    URI
    https://hdl.handle.net/20.500.12503/27359
    Collections
    • General Medicine

    DSpace software copyright © 2002-2016  DuraSpace
    Contact Us | Send Feedback
    TDL
    Theme by 
    Atmire NV
     

     

    Browse

    All of UNTHSC ScholarCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

    My Account

    Login

    DSpace software copyright © 2002-2016  DuraSpace
    Contact Us | Send Feedback
    TDL
    Theme by 
    Atmire NV